People with human immunodeficiency virus may experience an immune restoration syndrome during the lymphocyte recovery period following effective highly active antiretroviral therapy. In this syndrome, antigens that previously were ignored by the immune system now induce an exaggerated response with obvious clinical effects. Most cases have been associated with infectious agents such as cytomegalovirus or mycobacterium avium intracellulare. However, the sudden onset of sarcoidal granulomatous reactions have also been described in this setting.
Objective:
We report a 66-year-old HIV-positive man who presented with exacerbation of multiple foreign body granulomas decades after the original injuries. The presentation coincided with a significant rise in CD4 count after beginning highly active antiretroviral therapy.
Conclusion:
We propose that this case demonstrates another manifestation of the immune restoration syndrome and postulate that an uncontrolled Th1 response is the causative mechanism.
Get full access to this article
View all access options for this article.
References
1.
FrenchMJohnMMallalS. Immune restoration disease after treatment of immunodeficient HIV-infected patients with potent anti-retroviral therapy. Program and abstracts of 12th World AIDS Congress, 28 June–3 July 1998, Geneva, Switzerland, Abstract 340/22323.
BoyrazHWitmerJFrissenP. Cytomegalovirus (re) activation plays no role in the ocular vitritis observed after initiation of highly active antiretroviral therapy. AIDS1999; 13(7):867.
4.
KuppermanBPettyJRichmanD. Correlation between CD4+ counts and prevalence of cytomegalovirus retinitis and human immunodeficiency virus-related noninfectious retinal vasculopathy in patients with acquired immunodeficiency syndrome. Am J Ophthalmol1993; 115:575–582.
5.
GuidicePDurantJCounillonE. Mycobacterial cutaneous manifestations: A new sign of immune restoration in patients with acquired immunodeficiency syndrome. Arch Dermatol1999; 135:1129–1130.
6.
FrenchMLenzoNJohnM. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med2000; 1(2):107–115.
7.
FrenchMAHMallalSADawkinsRL. Zidovudine induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS1992; 6:1293–1297.
8.
PalellaFJDelaneyKMMoormanAC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med1998; 338:853–860.
9.
RaceEMAdelson-MittyJKregelGR. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet1998; 351:252–255.
10.
PhillipsPKwiatowskiMBCoplandM. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol1999; 20:122–128.
11.
FoudraineNAHovenkampENotermansDW. Immunopathology as a result of highly active antiretroviral therapy in HIV-1 infected patients. AIDS1999; 13:177–184.
12.
MallalSAJamesIRFrenchMAH. Detection of subclinical mycobacterium avium intracellulare complex infection in immunodeficient HIV-infected patients treated with zidovudine. AIDS1994; 8:1263–1269.
13.
JohnMFrenchMAH. Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust1998; 169:473–474.
14.
NaritaMAshkinDHollenderES. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med1998; 158:157–161.
15.
CasadoJLPerez-EliasMJMarti-BeldaP. Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors. J Acquir Immune Defic Syndr Hum Retrovirol1998; 19:130–134.
16.
FoxPBartonSFrancisN. Erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease. HIV Med2000; 1(1):10–18.
17.
AldeenTHayPDavidsonF. Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy. AIDS1998; 12:1719–1720.
18.
MartinezEGatellJMMoranY. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis1998; 27:1510–1513.
19.
CarrACooperDA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitors. Lancet1997; 349:995–996.
20.
MastroianniCMTrinchieriVSantopadreP. Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy. AIDS1998; 12:1939–1940.
21.
BrauNLeafHLWieczorekRL. Severe hepatitis in three AIDS patients treated with indinavir. Lancet1997; 349:924–925.
22.
MatsudaJGohlchiKYamanakaM. Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir. Lancet1997; 350:364.
23.
VentoSGarfanoTRenziniC. Enhancement of hepatitis C virus replication and liver damage in HIV co-infected patients on antiretroviral combination therapy. AIDS1998; 12:116–117.
24.
JohnMFlexmanJFrenchM. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?AIDS1998; 12:2289–2293.
25.
PialouxGLandauAEliaszewiczM. Rapidly evolving hepatitis C virus infection in HIV co-infected patients treated with HAART. Presented at 12th World AIDS Conference, 28 June–3 July 1998, Geneva, Switzerland, Abstract 22243.
26.
RockstrohJKTheisenAKaiserR. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV–HCV-coinfected haemophiliacs. AIDS1998; 12:829–830.
27.
ZylberbergHChaixMRabianC. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in co-infected subjects. Clin Infect Dis1998; 26:1104–1106.
WeirAWansborough-JonesM. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS1997; 11:1895–1896.
30.
MirmiraniPMaurerTHerndierB. Sarcoidosis in a patient with AIDS: A manifestation of immune restoration syndrome. J Am Acad Dermatol1999; 41:285–286.
31.
SilvestreJFAlbaresMPRamonR. Cutaneous intolerance to tattoos in a patient with human immunodeficiency virus: A manifestation of the immune restoration syndrome [Letter]. Arch Dermatol2001; 137(5):669–670.
32.
FrenchMAHCameronPUGrimsleyG. Correction of human immunodeficiency virus-associated depression of delayed-type hypersensitivity (DTH) after zidovudine therapy: DTH, CD4+ T-cell numbers, and epidermal Langerhans cell density are independent variables. Clin Immunol Immunopadiol1990; 55:86–96.
33.
GompelsMPattersonSRobertsMS. Increase in dendritic cell numbers, their function and the proportion uninfected during AZT therapy. Clin Exp Immunol1990; 112:34–353.
34.
KelleherADCarrAZaundersJ. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis1996; 173:321–329.
35.
TuralCRomeuJSireraG. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis1998; 177:1080–1083.
36.
BassKKMastrangeloMJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother1998; 47(1): 1–12.
37.
MastrangeloMJBerdDMaguireHJ. The immunoaugmenting effects of cancer chemotherapeutic agents. Semin Oncol1986; 13 (2): 186–194.
38.
KawabeYOchiA. Programmed cell death and extrathymic reduction of VB8+ CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature1991; 349(6306):245–248.
39.
KawabeYOchiA. Selective anergy of VB8+ CD4+ T cells in Staphylococcus enterotoxin B-primed mice. J Exp Med1990; 172(4):1065–1070.
40.
BosmaMJCarrollAM. The SCID mouse mutant: Definition, characterization, and potential uses. Annu Rev Immunol1991; 9:323–350.
41.
WilliamsOArociraLSMartinezC. Absence of peripheral clonal deletion and anergy in immune responses of T cell-reconstituted athymic mice. Eur J Immunol1994; 24(3):579–584.
42.
AversaFTabilioAVelardiA. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med1998; 339(17):1186–1193.
43.
PickerLJSiegelmanMH. Lymphoid tissues and organs. In: PaulWE, ed. Fundamental Immunology. New. York: Raven Press, 1993, p 145.
44.
DillySASloaneJPPsaltiIS, The cellular composition of human lymph nodes after allogenic bone marrow transplantation: An immunohistological study. J Pathol1986; 150(3):213–221.
45.
BloomBRModlinRLSalgameP. Stigma variations: Observations on suppressor T cells and leprosy. Annu Rev Immunol1992; 10:453–488.
46.
GeenenVKroemerG. Multiple ways to cellular immune tolerance. Immunol Today1993; 14(12):573–575.
47.
KaplanMH. Mycobacterial avium intracellulare (MAIS) reversal syndrome set off by highly active antiretroviral therapy (HAART). Improved immunity is not always good but it is better than no immunity. 5th Conference on Retroviruses and Opportunistic 1–5 February 1998, Abstract 726.
48.
TorianiFFreemanWDurandD. Evidence that HAART induced immune recovery vitritis in CMV retinitis patients is immune mediated. Presented at 12th World AIDS Conference; 28 June–3 July 1998, Geneva, Switzerland, Abstract 15.
49.
KomanduriKVViswanthanMNWiederED. Restoration of cytomegalovirus-specific CD4 T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med1998; 4:953–956.
50.
SmithKSkeltonHYeagerJ. Histologic features of foreign body reactions in patients infected with human immunodeficiency virus type 1. J Am Acad Dermatol1993; 28:470–476.
51.
MollerDR. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis1999; 16(1):24–31.
52.
SpieringsEDe BoerTZulianelloL. Novel mechanisms in the immunopathogenesis of leprosy nerve damage: The role of Schwann cells, T cells and Mycobacterium leprae. Immunol Cell Biol2000; 78(4):349–355.
